Martin Puzo

Martin Puzo

Auto-generated profile, based on publicly available information

Martin Puzo

GIMSO, Institute for Health Research Aragón, Hospital Universitario Miguel Servet, Zaragoza, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2023 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
RMRubén Martín
Rubén Martín
JIJordi Izquierdo-Serra
Jordi Izquierdo-Serra
SZSandro De Zanet
Sandro De Zanet
APAlba Parrado-Carrillo
Alba Parrado-Carrillo
GAGonzaga Garay Aramburu
Gonzaga Garay Aramburu
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura
Aim To explore associations between artificial intelligence (AI)-based fluid compartment quantifications and 12 months visual outcomes in OCT images from a real-world, multicentre, national cohort of naïve neovascular age-related macular degeneration (nAMD) treated eyes. Methods Demographics, visual acuity (VA), drug and number of injections data were collected using a validated web-based tool. Fluid compartment quantifications including intraretinal fluid (IRF), subretinal fluid (SRF) and pigment epithelial detachment (PED) in the fovea (1 mm), parafovea (3 mm) and perifovea (6 mm) were measured in nanoliters (nL) using a validated AI-tool. Results 452 naïve nAMD eyes presented a mean VA gain of +5.5 letters with a median of 7 injections over 12 months. Baseline foveal IRF associated poorer baseline (44.7 vs 63.4 letters) and final VA (52.1 vs 69.1), SRF better final VA (67.1 vs 59.0) and greater VA gains (+7.1 vs +1.9), and PED poorer baseline (48.8 vs 57.3) and final VA (55.1 vs 64.1). Predicted VA gains were greater for foveal SRF (+6.2 vs +0.6), parafoveal SRF (+6.9 vs +1.3), perifoveal SRF (+6.2 vs −0.1) and parafoveal IRF (+7.4 vs +3.6, all p<0.05). Fluid dynamics analysis revealed the greatest relative volume reduction for foveal SRF (−16.4 nL, −86.8%), followed by IRF (−17.2 nL, −84.7%) and PED (−19.1 nL, −28.6%). Subgroup analysis showed greater reductions in eyes with higher number of injections. Conclusion This real-world study describes an AI-based analysis of fluid dynamics and defines baseline OCT-based patient profiles that associate 12-month visual outcomes in a large cohort of treated naïve nAMD eyes nationwide.

1 February 2022 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura
APAlba Parrado-Carrillo
Alba Parrado-Carrillo
VNVuong Nguyen
Vuong Nguyen
LSLaura Sararols
Laura Sararols
GAGonzaga Garay Aramburu
Gonzaga Garay Aramburu
FGfrom the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group
from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group
Background: To study the visual outcomes of neovascular AMD (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) drugs at national level.Methods: Multicenter national database of nAMD eyes treated with anti‐VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat‐and‐extend (TAE) regimens. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) ETDRS letters at baseline and subsequent visits, number of injections and visits data were collected using a validated web‐based tool (Fight Retinal Blindness!).Results: 1273 eyes (1014 patients) were included, 971 treatment naïve (TN) and 302 previously treated (PT). Baseline VA (mean ± SD) was 57.5 (±19.5) and 62.2 (±17) (p > 0.001), and 24 months final VA was 60.4 (±21.2) and 58.8 (±21.1) (p = 0.326), respectively. Mean VA change at 12/24 months was +4.2/+2.9 letters in TN eyes and +0.1/−3.4 letters in PT eyes (p < 0.001/p < 0.001). The percentage of ≥15 letters gainers/losers at 24 months was 24.8%/14.5% in TN, and 10.3%/15.7% in PT eyes. The median number of injections/visits at 12 months was 7/9 in TN and 6/8 in PT (p = 0.002/p < 0.001) and at 24 months was 11/16 in TN and 11/14 in PT (p = 0.329/p < 0.001). Study drugs included ranibizumab (39.5%), aflibercept (41.2%) and bevacizumab (19.3%).Conclusion: Independent, large‐scale national audits are feasible if committed health care professionals are provided with efficient information technology systems to do them. The results described here represent an adequate measurement of the quality of care delivered nationwide and benchmark the clinical management of nAMD at a country level compared to other real‐world international cohorts.

1 July 2024 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
MGMarta Jiménez García
Marta Jiménez García
FSFrancisco J. Segura-Calvo
Francisco J. Segura-Calvo
MPMartín Puzo
Martín Puzo
Francisco J. CastroFrancisco J. Castro
Francisco J. Castro
OZon behalf of the UFR-ARCCA Group Zaragoza
on behalf of the UFR-ARCCA Group Zaragoza
Purpose: To describe gender differences in the biometric parameters of a large sample of patients with cataract. Cataract surgery has evolved from a vision restoration to a refractive procedure, and population-based studies are vital to optimize normative databases and postsurgical outcomes. Setting: Miguel Servet University Hospital, Zaragoza, Spain. Design: Retrospective single-center observational study. Methods: The study included 34 589 eyes (20 004 patients with cataract). Biometric data were obtained from IOL Master 700 and Pentacam HR. Linear mixed models were used to account for intereye correlation. HofferQST formula was used to calculate the hypothetical distribution of intraocular lens (IOL) power (arbitrary lens; A = 119.2). Results: Most biometric variables showed significant differences between sexes (P < .0001), such as 0.53 mm shorter eyes found in females, of which 0.16 mm are explained by shorter aqueous depth. Steeper anterior keratometries (∼0.75 diopter [D]) were found in women, to end up in no difference on anterior astigmatism magnitude, but different orientation (P < .0001). The distribution of IOL power differed between sexes (P < .001), with the interquartile range shifting 1 D toward more powerful lenses in women and odds ratio (power >26 D) = 2.26, P < .0001 (Fisher). Conclusions: Large sample size studies provide smaller margin of error, higher power, and controlled risk of reporting false (negative or positive) findings. Highly significant differences between sexes in ocular biometry were found; this supports the idea that including sex as a parameter in IOL calculation should be explored and may improve results. In addition, the distribution of IOL powers was provided, which may be useful for manufacturers and hospital stock planning.

23 January 2025 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
RMRubén Martín
Rubén Martín
JIJordi Izquierdo-Serra
Jordi Izquierdo-Serra
CBCarolina Bernal-Morales
Carolina Bernal-Morales
SZSandro De Zanet
Sandro De Zanet
GAGonzaga Garay Aramburu
Gonzaga Garay Aramburu
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura
Aim To evaluate the impact of fluid volume fluctuations quantified with artificial intelligence in optical coherence tomography scans during the maintenance phase and visual outcomes at 12 and 24 months in a real-world, multicentre, national cohort of treatment-naïve neovascular age-related macular degeneration (nAMD) eyes. Methods Demographics, visual acuity (VA) and number of injections were collected using the Fight Retinal Blindness tool. Intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), total fluid (TF) and central subfield thickness (CST) were quantified using the RetinAI Discovery tool. Fluctuations were defined as the SD of within-eye quantified values, and eyes were distributed according to SD quartiles for each biomarker. Results A total of 452 naïve nAMD eyes were included. Eyes with highest (Q4) versus lowest (Q1) fluid fluctuations showed significantly worse VA change (months 3–12) in IRF −3.91 versus 3.50 letters, PED −4.66 versus 3.29, TF −2.07 versus 2.97 and CST −1.85 versus 2.96 (all p<0.05), but not for SRF 0.66 versus 0.93 (p=0.91). Similar VA outcomes were observed at month 24 for PED −8.41 versus 4.98 (p<0.05), TF −7.38 versus 1.89 (p=0.07) and CST −10.58 versus 3.60 (p<0.05). The median number of injections (months 3–24) was significantly higher in Q4 versus Q1 eyes in IRF 9 versus 8, SRF 10 versus 8 and TF 10 versus 8 (all p<0.05). Conclusion This multicentre study reports a negative effect in VA outcomes of fluid volume fluctuations during the maintenance phase in specific fluid compartments, suggesting that anatomical and functional treatment response patterns may be fluid-specific.

21 September 2024 in Eye
Verified
Journal Article
Closed access
PDF file
MPMartín Puzo
Martín Puzo
PCPilar Calvo-Perez
Pilar Calvo-Perez
FBFrancisco De Asís Bartol-Puyal
Francisco De Asís Bartol-Puyal
JSJORGE SANCHEZ-MONROY
JORGE SANCHEZ-MONROY
RMRuben Martin-Pinardel
Ruben Martin-Pinardel
JZJavier Zarranz-Ventura
Javier Zarranz-Ventura

14 December 2020 in Retina
Verified
Journal Article
Open access
VNVuong Nguyen
Vuong Nguyen
MPMartin Puzo
Martin Puzo
JSJORGE SANCHEZ-MONROY
JORGE SANCHEZ-MONROY
Pierre-Henry GabriellePierre-Henry Gabrielle
Pierre-Henry Gabrielle
CCCatherine Creuzot-Garcher
Catherine Creuzot-Garcher
MGMark C. Gillies
Mark C. Gillies
Purpose: Assess the relationship between subretinal fluid (SRFL), intraretinal fluid, and visual outcomes of neovascular age-related degeneration in routine clinical practice. Methods: Treatment-naive eyes enrolled in the Fight Retinal Blindness! registry after January 2017 were identified. Lesion activity was graded at each visit as inactive, active not SRFL only (A-NSRFL only), or active SRFL only (A-SRFL only). Eyes were grouped based on initial activity as follows: 1) initially A-NSRFL only or 2) initially A-SRFL only, and their predominant activity status over 12 months was as follows: 1) mostly inactive, 2) mostly A-NSRFL only, or 3) mostly A-SRFL only. Results: Seven hundred and three eyes were eligible for analysis. Initially A-NSRFL only had a similar adjusted mean 12-month visual acuity change to initially A-SRFL eyes (5.7 vs. 6.9 letters; P = 0.165), but their final visual acuity was worse (62.5 vs. 67.5 letters at 12 months; P = 0.003). The adjusted mean 12-month visual acuity change between the predominant activity groups was significantly different (P = 0.005), with mostly inactive (7.6 letters) and mostly A-SRFL only (7.5 letters) eyes gaining more than mostly A-NSRFL only eyes (3.6 letters). Conclusion: Eyes with SRFL only had similar outcomes at 1 year to eyes that were mostly inactive. Intraretinal fluid was associated with worse visual outcomes, highlighting the importance of distinguishing between intraretinal fluid and SRFL when managing neovascular age-related degeneration.